Skip to main content
Psychedex
Article

4F-MPH Facts

Stimulant; Phenidate; Dopamine reuptake inhibitor

Description

4F-MPH (4-fluoromethylphenidate) is a synthetic stimulant of the substituted phenidate class. It blocks the clearance of dopamine and norepinephrine from the brain's synapses, producing the focused, alert stimulation characteristic of phenidate compounds.

Subjective effects include increased focus, wakefulness, rapid thinking, appetite suppression, and emotional flattening. The experience is characteristically mechanical — dry, task-oriented stimulation with minimal warmth or euphoria, closer to an amplified work state than a recreational high.

4F-MPH carries high dependence potential driven by strong DAT blockade,[1] and elevated heart rate and blood pressure are the primary acute dangers.[2] Its greater potency than methylphenidate means cardiovascular effects can appear at lower doses; one confirmed overdose required emergency sedation.[3]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight5 – 10 mgCommon10 – 15 mgStrong15 – 20 mgHeavy20+ mg

Starts in 30 – 60 minLasts 4 – 8 hoursAfter-effects 5 – 10 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Low
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
High

Tolerance

Builds
Moderate
Fully resets after
5 days
Carries over to
methylphenidate; ethylphenidate; isopropylphenidate; other phenidate analogs

Effectslikely at a common dose

Perception
none likely · 3 possible
Body
Wakefulness; Appetite suppression; Stimulation; +18 possible, including Insomnia, Vasoconstriction, Heart rate perception changes
Thinking
none likely · 15 possible, including Compulsive redosing urge
Feeling
none likely · 9 possible, including Anxiety, Anhedonia, Dysphoria
Self
none likely · 7 possible, including Craving, Ego inflation
Time
none likely · 2 possible
Awareness
none likely · 1 possible

Who shouldn't take it

Absolute
Severe cardiovascular disease; Concurrent MAOI use; Pheochromocytoma
Relative
Hypertension; Seizure disorders; Anxiety disorders; History of psychosis or bipolar disorder; Hepatic impairment; Pregnancy and lactation

Combinations62 recorded

Lethal (2)
Ibogaine; Tramadol
Dangerous (29)
Alpha-2 adrenergic receptor antagonist; Amphetamines; Benzodiazepines, Barbiturates; Ephedrine, Pseudoephedrine; Local anesthetics; MAOIs; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; SSRIs; Stimulants; Anticholinergics; Antipsychotics; Buspirone; Caffeine; Dopamine agonists; DXM; GHB, Baclofen; GHB, GBL; Ketamine, DXM, PCP; Lithium; NSAIDs; and 5 more, see full page
Caution (28)
See full page: psychedex.org/substances/4f-mph
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Liechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling — Swiss Medical Weekly doi:10.4414/smw.2015.14043
  2. [2]
    ^Silczuk A, Lewandowska A, Filip M, Atroszko PA, Podolec J, Galecka M, Madejek R, Czyzewski L (2025) Current insights into the safety and adverse effects of methylphenidate in children, adolescents, and adults - narrative review — Pharmacological Reports doi:10.1007/s43440-025-00763-0
  3. [3]
    ^Papa P, Valli A, Di Tuccio M, Frison G, Zancanaro F, Buscaglia E, Locatelli CA (2019) Analytically Confirmed Intoxication by 4-Fluoromethylphenidate, an Analog of Methylphenidate — Journal of Analytical Toxicology doi:10.1093/jat/bkz001
Print version
Report an issue